UPDATE: Cowen Starts Cardiff Oncology (CRDF) at Outperform

November 30, 2020 5:37 AM EST
Get Alerts CRDF Hot Sheet
Price: $5.46 +5.41%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 8 | New: 71
Trade Now! 
Join SI Premium – FREE
(Updated - November 30, 2020 6:08 AM EST)

(updated to add analyst comments)

Cowen analyst Marc Frahm initiates coverage on Cardiff Oncology (NASDAQ: CRDF) with an Outperform rating.

The analyst commented, "Cardiff’s sole asset onvansertib is a selective, orally available PLK1 inhibitor. Early Phase I data for onvansertib in combination with 2L SOC chemo + bevacizumab in KRAS-mutant mCRC suggest potential additive efficacy vs. historical comparators. Updated data are expected at ASCO-GI in January. We believe success in mCRC would generate upside and are initiating coverage with an Outperform rating."

For an analyst ratings summary and ratings history on Cardiff Oncology click here. For more ratings news on Cardiff Oncology click here.

Shares of Cardiff Oncology closed at $21.92 yesterday.

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Cowen & Co